Tissue-specific overexpressed antigens such as HER-2 are attractive tumour targets because of their prevalence across patients and indications, and previous validation by other therapeutic modalities.2 However, HER-2-specific CAR-T cell immunotherapy has been hampered by the development of pulmonary toxicity in the first patient treated with the second generation of HER-2 targeting CAR-T cells. Here, ERBB2 is linked to neoplasm.